BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32699415)

  • 1. Signalling input from divergent pathways subverts B cell transformation.
    Chan LN; Murakami MA; Robinson ME; Caeser R; Sadras T; Lee J; Cosgun KN; Kume K; Khairnar V; Xiao G; Ahmed MA; Aghania E; Deb G; Hurtz C; Shojaee S; Hong C; Pölönen P; Nix MA; Chen Z; Chen CW; Chen J; Vogt A; Heinäniemi M; Lohi O; Wiita AP; Izraeli S; Geng H; Weinstock DM; Müschen M
    Nature; 2020 Jul; 583(7818):845-851. PubMed ID: 32699415
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stat5-deficient hematopoiesis is permissive for Myc-induced B-cell leukemogenesis.
    Wang Z; Medrzycki M; Bunting ST; Bunting KD
    Oncotarget; 2015 Oct; 6(30):28961-72. PubMed ID: 26338970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Bruton's tyrosine kinase in B cells and malignancies.
    Pal Singh S; Dammeijer F; Hendriks RW
    Mol Cancer; 2018 Feb; 17(1):57. PubMed ID: 29455639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel indoloquinoline derivative, IQDMA, inhibits STAT5 signaling associated with apoptosis in K562 cells.
    Yang SH; Chien CM; Su JC; Chen YL; Chang LS; Lin SR
    J Biochem Mol Toxicol; 2008; 22(6):396-404. PubMed ID: 19111001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways.
    Dobbin E; Graham C; Corrigan PM; Thomas KG; Freeburn RW; Wheadon H
    Exp Hematol; 2009 Jan; 37(1):111-121. PubMed ID: 19100521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sleeping Beauty transposon screen identifies signaling modules that cooperate with STAT5 activation to induce B-cell acute lymphoblastic leukemia.
    Heltemes-Harris LM; Larson JD; Starr TK; Hubbard GK; Sarver AL; Largaespada DA; Farrar MA
    Oncogene; 2016 Jun; 35(26):3454-64. PubMed ID: 26500062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies.
    Freund P; Kerenyi MA; Hager M; Wagner T; Wingelhofer B; Pham HTT; Elabd M; Han X; Valent P; Gouilleux F; Sexl V; Krämer OH; Groner B; Moriggl R
    Leukemia; 2017 Oct; 31(10):2132-2142. PubMed ID: 28074064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a c-Jun N-terminal kinase-2-dependent signal amplification cascade that regulates c-Myc levels in ras transformation.
    Mathiasen DP; Egebjerg C; Andersen SH; Rafn B; Puustinen P; Khanna A; Daugaard M; Valo E; Tuomela S; Bøttzauw T; Nielsen CF; Willumsen BM; Hautaniemi S; Lahesmaa R; Westermarck J; Jäättelä M; Kallunki T
    Oncogene; 2012 Jan; 31(3):390-401. PubMed ID: 21706057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
    Marampon F; Ciccarelli C; Zani BM
    Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.
    Mizuki M; Fenski R; Halfter H; Matsumura I; Schmidt R; Müller C; Grüning W; Kratz-Albers K; Serve S; Steur C; Büchner T; Kienast J; Kanakura Y; Berdel WE; Serve H
    Blood; 2000 Dec; 96(12):3907-14. PubMed ID: 11090077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition.
    Moyo TK; Wilson CS; Moore DJ; Eischen CM
    Oncogene; 2017 Aug; 36(32):4653-4661. PubMed ID: 28368423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the Raf-1 kinase by cyclic AMP agonists causes apoptosis of v-abl-transformed cells.
    Weissinger EM; Eissner G; Grammer C; Fackler S; Haefner B; Yoon LS; Lu KS; Bazarov A; Sedivy JM; Mischak H; Kolch W
    Mol Cell Biol; 1997 Jun; 17(6):3229-41. PubMed ID: 9154822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STAT5 represses BCL6 expression by binding to a regulatory region frequently mutated in lymphomas.
    Walker SR; Nelson EA; Frank DA
    Oncogene; 2007 Jan; 26(2):224-33. PubMed ID: 16819511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic c-Myc-induced lymphomagenesis is inhibited non-redundantly by the p19Arf-Mdm2-p53 and RP-Mdm2-p53 pathways.
    Meng X; Carlson NR; Dong J; Zhang Y
    Oncogene; 2015 Nov; 34(46):5709-17. PubMed ID: 25823025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line.
    Shi Z; Hodges VM; Dunlop EA; Percy MJ; Maxwell AP; El-Tanani M; Lappin TR
    Mol Cancer Res; 2010 Apr; 8(4):615-26. PubMed ID: 20353997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STAT5 outcompetes STAT3 to regulate the expression of the oncogenic transcriptional modulator BCL6.
    Walker SR; Nelson EA; Yeh JE; Pinello L; Yuan GC; Frank DA
    Mol Cell Biol; 2013 Aug; 33(15):2879-90. PubMed ID: 23716595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rac1 signalling modulates a STAT5/BCL-6 transcriptional switch on cell-cycle-associated target gene promoters.
    Barros P; Lam EW; Jordan P; Matos P
    Nucleic Acids Res; 2012 Sep; 40(16):7776-87. PubMed ID: 22723377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential STAT5 signaling by ligand-dependent and constitutively active cytokine receptors.
    Moucadel V; Constantinescu SN
    J Biol Chem; 2005 Apr; 280(14):13364-73. PubMed ID: 15677477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival.
    Katerndahl CDS; Heltemes-Harris LM; Willette MJL; Henzler CM; Frietze S; Yang R; Schjerven H; Silverstein KAT; Ramsey LB; Hubbard G; Wells AD; Kuiper RP; Scheijen B; van Leeuwen FN; Müschen M; Kornblau SM; Farrar MA
    Nat Immunol; 2017 Jun; 18(6):694-704. PubMed ID: 28369050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.